The TB Diagnostic Market was valued for $2,066.70 million in 2022 and is estimated to reach $3,102.20 million by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032.
Tuberculosis (TB) is a bacterial infection caused by mycobacterium tuberculosis that primarily affects the lungs. It is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. TB is mainly diagnosed with the TB skin test (TST) and TB blood tests.
The growth of the TB diagnostic market is driven by an increase in the number of R&D activities, the surge in expenditure on product development by the government & private organizations, increase in the technological advancements of the diagnostics test’s products, and an upsurge in the number of hospital visits of the patients for TB screening. Furthermore, the increase in the prevalence of Tb infection drives the growth of the market. For instance, according to the World Health Organization (WHO), in 2021, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide.
Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.
However, BCG vaccination, inaccurate pap smear testing, and the availability of other types of screening for TB are expected to hinder the growth of the market.
The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific.
Tuberculosis (TB) is a bacterial infection caused by mycobacterium tuberculosis that primarily affects the lungs. It is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. TB is mainly diagnosed with the TB skin test (TST) and TB blood tests.
The growth of the TB diagnostic market is driven by an increase in the number of R&D activities, the surge in expenditure on product development by the government & private organizations, increase in the technological advancements of the diagnostics test’s products, and an upsurge in the number of hospital visits of the patients for TB screening. Furthermore, the increase in the prevalence of Tb infection drives the growth of the market. For instance, according to the World Health Organization (WHO), in 2021, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide.
Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.
However, BCG vaccination, inaccurate pap smear testing, and the availability of other types of screening for TB are expected to hinder the growth of the market.
The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tb diagnostic market analysis from 2022 to 2032 to identify the prevailing tb diagnostic market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the tb diagnostic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global tb diagnostic market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Criss-cross segment analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Type
- Culture based diagnosis
- Sputum test
- Rapid Molecular Diagnosis
- Others
By End-User
- Hospitals
- Diagnostic labs
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Abbott Laboratories
- Becton Dickinson & Company
- Molbio Diagnostics Pvt. Ltd.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Hologic Inc.
- Thermo Fisher Scientific Inc.
- bioMerieux SA
- F. Hoffmann-La Roche Ltd.
- Qiagen NV.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: TB DIAGNOSTIC MARKET, BY TYPE
CHAPTER 5: TB DIAGNOSTIC MARKET, BY END-USER
CHAPTER 6: TB DIAGNOSTIC MARKET, BY REGION
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, the tb diagnostic market was valued at $2.1 billion in 2022, and is estimated to reach $3.1 billion by 2032, growing at a CAGR of 4.1% from 2023 to 2032.Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs and also other parts of the body. A persistent cough that lasts more than three weeks is the most common symptom of tuberculosis. The BCG vaccination is given to protect individuals from TB infections. Based on the organ affected, the common types of tuberculosis include pulmonary tuberculosis, brain tuberculosis, and skeletal tuberculosis.
A number of factors such as rise in the number of cigarette smokers, large number of patients suffering from HIV infection, undernutrition, diabetes, and alcohol use disorders contribute to the growing prevalence of TB. Various studies have shown that smoking damages the lungs, making smokers more susceptible to TB infection. In addition, this increase in the prevalence of TB helps boost the demand for TB diagnostics. Similarly, the increase in R&D activities for the diagnostic tests of tb with maximum effectiveness of the test product augments the growth of the market. Moreover, the research activities are funded by private organizations or the government authorities for the study of infectious disease diagnostics. Hence, the growth in the expenditure from these authorities boosts the research activities that help in the increased use of TB diagnostic thereby driving the growth of the market.
Furthermore, acquisition, new product approval and product launch in market drives the growth of market For instance, in January 2023, Viatris Inc., a global healthcare company, announced its complete acquisition of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. In addition, a rise in awareness about the effectiveness of TB diagnostic, surge in incidence of dry eye syndrome, increase in availability & affordability of healthcare treatment and rise in number of hospital admissions contributes to the growth of mMoreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.
Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection. The market also offers growth opportunities to the key players in the market. The target population is in tremendous need of cost-effective services in regions like Europe and Asia-Pacific. Hence, challenges to cater the unmet needs of the target population provide growth opportunities. Online medical services have gained high traction in the last 4 years. As a result, engaged stakeholders in the industry have partnered with existing delivery services organizations.
The TB diagnostic market is segmented into drug, dosage form, distribution channel, and region. On the The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific. The players in the market have been actively engaged in the adoption of various strategies such as acquisition, product launch, and partnership to remain competitive and gain an advantage over the competitors in the market.
Key Market Insights (Updated)
On the basis of Type, the rapid molecular diagnosis segment was the major share contributor in 2022.By end user, the diagnostic labs segment dominated the market in 2022, and the ointments segment is expected to grow at the fastest CAGR during the forecast period.
Region wise, North America garnered the largest revenue share in 2022, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Abbott Laboratories
- Becton Dickinson & Company
- Molbio Diagnostics Pvt. Ltd.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Hologic Inc.
- Thermo Fisher Scientific Inc.
- bioMerieux SA
- F. Hoffmann-La Roche Ltd.
- Qiagen NV.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
